Education
About Us
Working with TipRanks
Follow Us
QuantumPharm, Inc. (HK:2228)
:2228
2228 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$3.05 - HK$16.20
Previous CloseN/A
Volume31.51M
Average Volume (3M)190.34M
Market Cap
HK$42.04B
Enterprise ValueHK$17.30B
Total Cash (Recent Filing)HK$3.39B
Total Debt (Recent Filing)HK$163.57M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Mar 27, 2026EPS EstimateN/A
Last Dividend Ex-Date
Jun 13, 2016Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding4,017,001,700
10 Day Avg. Volume284,839,556
30 Day Avg. Volume190,341,685
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.50Price Target Upside2.14% Upside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Financial StrengthThe company further strengthened its financial position by completing two fundraising placements raising HK$3.2bn to enhance its cash reserves and fund future growth initiatives.
PartnershipsXtalPi's expanding ecosystem of partnerships reflects its strong commercialization potential across AI and robotics-enabled industries.
Revenue GrowthXtalPi leverages its proprietary AI-powered R&D platform to deliver stable and accelerating revenue growth across two core business areas: drug discovery and intelligent robotics.
Bears Say
Commercialization SustainabilityRisks relating to R&D progress of drug candidates in partnerships, sustainability of commercialization, and shareholder sell-off.
R&D Pipeline RisksRisks include potential delays in partnered R&D pipelines, uncertainty in commercialization sustainability, and possible sell-off following lock-up expiry.
QuantumPharm, Inc. News
2228 FAQ
What was QuantumPharm, Inc.’s price range in the past 12 months?
QuantumPharm, Inc. lowest stock price was HK$3.05 and its highest was HK$16.20 in the past 12 months.
What is QuantumPharm, Inc.’s market cap?
QuantumPharm, Inc.’s market cap is HK$42.04B.
When is QuantumPharm, Inc.’s upcoming earnings report date?
QuantumPharm, Inc.’s upcoming earnings report date is Mar 27, 2026 which is in 211 days.
How were QuantumPharm, Inc.’s earnings last quarter?
QuantumPharm, Inc. released its earnings results on Aug 27, 2025. The company reported HK$0.016 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.016.
Is QuantumPharm, Inc. overvalued?
According to Wall Street analysts QuantumPharm, Inc.’s price is currently Undervalued.
Does QuantumPharm, Inc. pay dividends?
QuantumPharm, Inc. pays a Notavailable dividend of HK$0.007 which represents an annual dividend yield of N/A. See more information on QuantumPharm, Inc. dividends here
What is QuantumPharm, Inc.’s EPS estimate?
QuantumPharm, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does QuantumPharm, Inc. have?
QuantumPharm, Inc. has 4,017,001,700 shares outstanding.
What happened to QuantumPharm, Inc.’s price movement after its last earnings report?
QuantumPharm, Inc. reported an EPS of HK$0.016 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.676%.
Which hedge fund is a major shareholder of QuantumPharm, Inc.?
Currently, no hedge funds are holding shares in HK:2228
QuantumPharm, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$10.50 (2.14% Upside)
HK$10.50 (2.14% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.08%
Trailing 12-Months
Company Description
QuantumPharm, Inc.
XtalPi Holdings Limited, an investment holding company, provides drug discovery and intelligent automation solutions in China, the United States, Europe, South Korea, and Japan. The company's drug discovery solutions cover the whole drug discovery and research process, including target validation, hit identification, lead generation, lead optimization, and PCC nomination covering various modalities, which comprise small molecules, antibodies, peptides, ADC, and PROTAC. Its intelligent automation solutions focus on AI- and automation-enabled novel drug and materials discovery and research. The company was formerly known as QuantumPharm Inc. and changed its name to XtalPi Holdings Limited in December 2024. XtalPi Holdings Limited was founded in 2015 and is headquartered in Shenzhen, China.
Technical Analysis
WuXi XDC Cayman, Inc.
―
Henan Jinyuan Hydrogenated Chemicals Co., Ltd. Class H
―
Hightide Therapeutics Inc
―
RoboSense Technology Company., Ltd
―
Qyuns Therapeutics Co., Ltd. Class H
―
Ownership Overview
―
Insiders
0.04%
Mutual Funds
― Other Institutional Investors
99.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---